Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 2:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 2,286 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Open Label Extension Clear all
Completed Phase 2 Interventional Results available

Extension Study of Proellex in Women Who Have Previously Completed Study ZPU 003

NCT00958334
View directory record Official record
Conditions
Uterine Fibroids
Interventions
Proellex®
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
11
States / cities
Phoenix, Arizona • San Diego, California • Denver, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2019 · Synced Oct 26, 2026, 2:46 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Nilotinib (AMN107) Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib

NCT00471328
View directory record Official record
Conditions
Gastrointestinal Stromal Tumors
Interventions
Nilotinib, Best Supportive Care (BSC) +/- imatinib or sunitinib
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
11
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2012 · Synced Oct 26, 2026, 2:46 PM EDT
Terminated Phase 1 Interventional

A Study of PLX73086 in Advanced Solid Tumors and Locally Advanced or Refractory Tenosynovial Giant Cell Tumor

NCT02673736
View directory record Official record
Conditions
Solid Tumors, Tenosynovial Giant Cell Tumor, Synovitis, Pigmented Villonodular
Interventions
PLX73086
Drug
Lead sponsor
Plexxikon
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Scottsdale, Arizona • Detroit, Michigan • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2018 · Synced Oct 26, 2026, 2:46 PM EDT
Recruiting Phase 2 Interventional

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus

NCT07260877
View directory record Official record
Conditions
Cutaneous Lupus Erythematosus (CLE), Systemic Lupus Erythematosus, SLE, SLE (Systemic Lupus), CLE
Interventions
VENT-03, Placebo
Drug
Lead sponsor
Ventus Therapeutics U.S., Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
15
States / cities
Beverly Hills, California • Clearwater, Florida • DeBary, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 26, 2026, 2:46 PM EDT
Completed Phase 3 Interventional

A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease

NCT00074971
View directory record Official record
Conditions
Fabry Disease
Interventions
Fabrazyme (agalsidase beta)
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
16 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
14
States / cities
Los Angeles, California • San Francisco, California • Coral Springs, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Oct 26, 2026, 2:46 PM EDT
Recruiting Phase 1Phase 2 Interventional

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

NCT05099172
View directory record Official record
Conditions
Advanced Non-small Cell Lung Cancer, EGFR Mutation, HER2 Mutation
Interventions
BAY2927088_formulation A, BAY2927088_formulation B_1, BAY2927088_formulation B_2, BAY2927088_formulation B_3
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
11
States / cities
Gilbert, Arizona • Duarte, California • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 26, 2026, 2:46 PM EDT
Completed Phase 1 Interventional

A Study on Safety and Tolerability of SAR425899 in Overweight to Obese Subjects and Type 2 Diabetes Mellitus Patients Not Requiring Anti-Diabetic Pharmacotherapy With an Optional 6-month Safety Extension Period

NCT03414736
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
SAR425899
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
3
States / cities
Saint Paul, Minnesota • Knoxville, Tennessee • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 26, 2026, 2:46 PM EDT
Recruiting Phase 2 Interventional

A Study of Quinacrine in Participants With Cutaneous Lupus Erythematosus

NCT07694336
View directory record Official record
Conditions
Cutaneous Lupus Erythematosus (CLE)
Interventions
Quinacrine Hydrochloride, Placebo
Drug · Other
Lead sponsor
Victoria Werth
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 26, 2026, 2:46 PM EDT
Completed Phase 3 Interventional

Extension Study for 2993-112

NCT01789957
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
AC2993
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
16 Years to 75 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
219
States / cities
Anniston, Alabama • Birmingham, Alabama • Eclectic, Alabama + 162 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2015 · Synced Oct 26, 2026, 2:46 PM EDT
Completed Phase 3 Interventional Results available

Clinical Endpoint Bioequivalence Study of Test and Reference Inhalation Products in Patients With COPD With Device Robustness

NCT03137992
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Placebo, Test Product (tiotropium bromide inhalation powder), Reference Product (Spiriva®)
Drug
Lead sponsor
Lupin, Inc.
Industry
Eligibility
40 Years and older
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
34
States / cities
Andalusia, Alabama • Jasper, Alabama • Glendale, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2021 · Synced Oct 26, 2026, 2:46 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Paediatric Subjects With Congenital Factor XIII A-subunit Deficiency

NCT01253811
View directory record Official record
Conditions
Congenital Bleeding Disorder, Congenital FXIII Deficiency
Interventions
catridecacog
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
1 Year to 6 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Boston, Massachusetts • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 24, 2016 · Synced Oct 26, 2026, 2:46 PM EDT
Completed Phase 3 Interventional Results available

Ambulatory Blood Pressure Monitoring (ABPM) Extension Study of Oral Testosterone Undecanoate in Hypogonadal Men

NCT04467697
View directory record Official record
Conditions
Hypogonadism, Male
Interventions
SOV2012-F1
Drug
Lead sponsor
Marius Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
19
States / cities
Birmingham, Alabama • Mobile, Alabama • Aventura, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2024 · Synced Oct 26, 2026, 2:46 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Effect of Tocilizumab + Methotrexate on Prevention of Structural Joint Damage in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA)

NCT00106535
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
tocilizumab [RoActemra/Actemra], Placebo, Methotrexate
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
61
States / cities
Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2014 · Synced Oct 26, 2026, 2:46 PM EDT
Completed Phase 3 Interventional Results available

A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD

NCT01371708
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
DVS SR
Drug
Lead sponsor
Pfizer
Industry
Eligibility
7 Years to 17 Years
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
35
States / cities
Birmingham, Alabama • Tucson, Arizona • Imperial, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2017 · Synced Oct 26, 2026, 2:46 PM EDT
Completed Not applicable Interventional Results available

Development of a Multifunctional Rehabilitation Device for Persons With Parkinson's Disease

NCT05586490
View directory record Official record
Conditions
Parkinson Disease
Interventions
Multifunctional RehabilitationDevice (MRD), existing standard rehabilitation device
Device
Lead sponsor
University of Michigan
Other
Eligibility
50 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 26, 2026, 2:46 PM EDT
Completed Phase 4 Interventional

Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab

NCT04377555
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing
Interventions
Ocrelizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
26
States / cities
Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 26, 2026, 2:46 PM EDT
Recruiting Phase 2Phase 3 Interventional

Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type 1 (ADH1)

NCT07080385
View directory record Official record
Conditions
Autosomal Dominant Hypocalcemia Type 1 (ADH1)
Interventions
Encaleret
Drug
Lead sponsor
Calcilytix Therapeutics, Inc., a BridgeBio company
Industry
Eligibility
0 Years to 17 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
4
States / cities
New Haven, Connecticut • Washington D.C., District of Columbia • Jacksonville, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 26, 2026, 2:46 PM EDT
Not yet recruiting Phase 3 Interventional

Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis

NCT07441408
View directory record Official record
Conditions
Pulmonary Fibrosis
Interventions
BMS-986278
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
Not listed
Enrollment
2,380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Birmingham, Alabama • Ocala, Florida • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 26, 2026, 2:46 PM EDT
Completed Early Phase 1 Interventional

A Feasibility Study of Topical Cannabinoids for Treatment of Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS) in Adults With Hormone Receptor-Positive Breast Cancer (CanAroma)

NCT05935891
View directory record Official record
Conditions
Musculoskeletal Syndrome
Interventions
CBD-dominant, THC dominant
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 26, 2026, 2:46 PM EDT
Completed Not applicable Interventional Results available

Gel-One Treatment in Knee Osteoarthritis

NCT01934218
View directory record Official record
Conditions
Osteoarthritis Knee
Interventions
Gel-One, PBS
Device
Lead sponsor
Seikagaku Corporation
Industry
Eligibility
40 Years to 80 Years
Enrollment
814 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
41
States / cities
Birmingham, Alabama • Sheffield, Alabama • Phoenix, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Oct 26, 2026, 2:46 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis

NCT01860976
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Abatacept, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
489 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
17
States / cities
Phoenix, Arizona • Colorado Springs, Colorado • Bridgeport, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Oct 26, 2026, 2:46 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS)

NCT05130450
View directory record Official record
Conditions
Familial Chylomicronemia Syndrome
Interventions
Olezarsen
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
7
States / cities
Huntington Beach, California • Boca Raton, Florida • Park Ridge, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2025 · Synced Oct 26, 2026, 2:46 PM EDT
Completed Phase 3 Interventional

A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough

NCT05599191
View directory record Official record
Conditions
Cough, Refractory Chronic Cough
Interventions
BLU-5937, Placebo
Drug
Lead sponsor
Bellus Health Inc. - a GSK company
Industry
Eligibility
18 Years to 80 Years
Enrollment
957 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
67
States / cities
Jasper, Alabama • Litchfield Park, Arizona • Scottsdale, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 26, 2026, 2:46 PM EDT
Active, not recruiting Phase 3 Interventional

An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis

NCT04130997
View directory record Official record
Conditions
Relapsing Multiple Sclerosis (RMS)
Interventions
Ublituximab
Biological
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2032
U.S. locations
19
States / cities
Pasadena, California • Denver, Colorado • Miami, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 26, 2026, 2:46 PM EDT